Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
2013-2014: The orthotopic hypopharyngeal tumor mouse model was established using the human hypopharyngeal carcinoma-derived FaDu cell line. The luciferase-stable FaDu cell line was also acquired. IVIS (in vivo bioluminescence/fluorescence imaging system) were utilized to monitor the hypopharyngeal tumor model during cell engraftment, tumor progression, and treatment response. 2014-2015: Maternity and parental leave. 2016-2017: Tailor-maid drug delivery system was developed by ligand-functionalized polymeric micelles. Tumor accumulation and anti-tumor activity of the micelle was assessed using the IVIS. Pharmacokinetics and tumor distribution of the micelle was investigated using the intravital confocal laser scanning microscopy.
|